linjc16/ctgov huggingface dataset:
Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging

Study Overview
=================
Brief Summary
-----------------
The investigators will obtain human skin specimen (sized approximately 1 cm x 1 cm) for dermatological surgical patients in National Taiwan University Hospital, after informed consent was obtained. Human skin keratinocytes, fibroblasts, and melanocytes will be cultured from the human skin specimen. The three dimensional images of these cultured cells will be observed by a ultra-high resolution 3-dimensional optical coherence tomography.

Detailed Description
-----------------
The investigators will obtain human skin specimen (sized approximately 1 cm x 1 cm) for dermatological surgical patients in National Taiwan University Hospital, after informed consent was obtained. Human skin keratinocytes, fibroblasts, and melanocytes will be cultured from the human skin specimen. The three dimensional images of these cultured cells will be observed by a ultra-high resolution 3-dimensional optical coherence tomography.

Official Title
-----------------
Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging

Conditions
-----------------
Optical Coherence Tomography, Skin Cell Imaging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 20 to 100. People who received benign skin tumor removal in dermatological surgical unit. OR People who received skin grafts (full thickness or split thickness) for reconstruction of surgical wounds after removing malignant skin cancer. Exclusion Criteria: Age less than 20 years old, Psychiatric patients, Pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
optical coherence tomography, cell imaging
Assessment of Hydration Status Using Bioelectrical Impedance Vector Analysis

Study Overview
=================
Brief Summary
-----------------
The state of hyperhydration in critically ill patients with acute kidney injury (AKI) is associated with increased mortality. Bioelectrical impedance vector analysis (BIVA) appears to be a viable method to access the fluid status of critical patients but has never been evaluated in critical patients with AKI. The objective of this study is to evaluate the hydration status using BIVA in critical patients under intensive care at the time of AKI diagnosis and to correlate this measurement with mortality. A sample of 224 patients with AKI will be evaluated by BIVA and followed until they are discharged or death in intensive care unit and the BIVA vectors will be analysed to define differences in hydration characteristics from each group.

Detailed Description
-----------------
Patients admitted to Intensive Care Unit (ICU) will be assessed by BIVA at the moment of the AKI diagnosis. They will be followed up to 12 weeks, until hospital discharge or death. The association between survival and hydration status, as assessed by BIVA in the first AKI day, will be tested.

Official Title
-----------------
Assessment of Hydration Status Using Bioelectrical Impedance Vector Analysis in Critical Patients With Acute Kidney Injury

Conditions
-----------------
Acute Kidney Injury, Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years who developed acute kidney injury after admission in Intensive Care Unit Exclusion Criteria: Chronic kidney injury, dialysis-dependent chronic kidney injury, acute kidney injury before ICU admission, kidney transplant, morbidity obesity and limb amputation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| critical patients with AKI<br>Critical patients with AKI will be followed up to 12 weeks after diagnosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of survivors in patients with AKI diagnosis during ICU | Patients admitted in ICU will be followed up to 2 weeks after AKI diagnosis and survival will be analyzed according to their hydration status assessed by BIVA. | Up to 12 weeks after AKI diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute kidney injury, intensive care unit, bioelectrical impedance analysis
Validation Study of the Korean Version of the EORTC QLQ-HDC29

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).

Official Title
-----------------
Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29

Conditions
-----------------
Quality of Life After Stem Cell Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are aged more than 18 years Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT) Patients who agree with the informed consent Exclusion Criteria: Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reliability and validity of the Korean version of the EORTC HDC-29 | Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency. Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires. | at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT) |
Thermal Imaging in Neonates: A Feasibility Study in Healthy Babies and Babies With Suspected TTN

Study Overview
=================
Brief Summary
-----------------
This is a study to evaluate thermal imaging as a technology to monitor the normal clearing of amniotic fluid from healthy newborns and newborns suspected of having a condition called transient tachypnea of the newborn, or TTN. Thermal images are taken using an imaging device that attaches to an iPhone. This device, commercially known as FLIR ONE, creates a non-identifiable image based on the heat pattern of an object. In this case, the object is a child's chest and back. It does not emit any radiation like an x-ray does.

Official Title
-----------------
Thermal Imaging in Neonates: a Feasibility Study in Healthy Babies and Babies With Suspected Transient Tachypnea of the Newborn (TTN)

Conditions
-----------------
Thermal Imaging, Neonatal Pneumonia, Tachypnea

Intervention / Treatment
-----------------
* Device: Thermal Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (healthy and suspected TTN babies): Full term (greater than or equal to 37 weeks gestation) less than 3 days old born via normal vaginal delivery Inclusion Criteria (only for suspected TTN babies): neonatologist assesses baby as possibly having TTN chest x-ray done as part of evaluation for TTN no other significant co-morbid conditions present Exclusion Criteria: parents do not consent to have baby participate

Ages Eligible for Study
-----------------
Maximum Age: 3 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Thermal imaging<br>All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone. | Device: Thermal Imaging<br>* FLIR ONE attachment to an iPhone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| asymmetric heat distribution | thermal imaging will be used to capture asymmetric heat distribution across lung fields | within the first 3 days of life | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy neonate, tachypnea, thermal imaging, pneumonia
Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to examine the effect of alpha-neurofeedback while subjects listen to a noise on tinnitus.

Official Title
-----------------
Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus

Conditions
-----------------
Tinnitus

Intervention / Treatment
-----------------
* Behavioral: Neurofeedback


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Duration of Tinnitus >= 6 months and <= 20 years Subjective Tinnitus Exclusion Criteria: History of neurological or more than mild psychiatric diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neurofeedback<br> | Behavioral: Neurofeedback<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of tinnitus distress using the Tinnitus Questionaire |  | Before the first and after the last session. | 
| Cortical Alpha Power |  | Before the first and after the last session |
A Comparison of Two Instruments for Stabilization of the Cervix During Office Procedures

Study Overview
=================
Brief Summary
-----------------
An Allis clamp causes less pain and bleeding than a single tooth tenaculum when used for mobilization of the cervix during common gynecologic office procedures. The primary object is to determine the presence of a difference in pain perception between the two instruments. The secondary objective is to evaluate the differences in the frequency of bleeding, that requires treatment, after removal of the instrument and the need to use an alternative instruments.

Official Title
-----------------
A Comparison of Two Instruments for Stabilization of the Cervix During Office Procedures

Conditions
-----------------
Comparing Two Clamps for Mobilization of the Cervix During Common Gynecologic Office Procedures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Between 18 and 89 years of age Undergoing an IUD placement Exclusion Criteria: IUD placement within the last 6 months Active cervical or pelvic infection pregnant Patient taking coagulation medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Allis<br> | |
| Tenaculum<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A comparison of two instruments for stabilization of the cervix during office procedures | Primary - to determine the presence of a difference in pain perception between the two instruments. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A comparison of two instruments for stabilization of the cervix during office procedures | Secondary - To evaluate the differences in the frequency of bleeding, that required treatment, after removal of the instruct and the need to use an alternative instrument. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervix, Allis, Tenaculum, gynecology
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)

Study Overview
=================
Brief Summary
-----------------
A study to evaluate MK0476 and Fluticasone to control asthma in patients with mild persistent asthma.

Official Title
-----------------
A Double-Blind, Randomized, Double-Dummy, Multicenter Study to Evaluate and Compare Oral Montelukast and Inhaled Fluticasone in the Control of Asthma for 6- to 14-Year-Olds With Mild Persistent Asthma

Conditions
-----------------
Asthma, Bronchial

Intervention / Treatment
-----------------
* Drug: MK0476, montelukast sodium / Duration of Treatment: 1 Year
* Drug: Comparator : fluticasone propionate / Duration of Treatment: 1 Year


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is male or female, 6-14 years of age with mild persistent asthma Patient has a history of the following symptoms: wheezing, chest tightness, cough, etc. Patient has asthma diagnosed by a doctor Exclusion Criteria: Patient is hospitalized Patient has had major surgery or participated in another clinical trial in the last 4 weeks Patient has been on a breathing tube for asthma

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0476, montelukast sodium / Duration of Treatment: 1 Year|nan|
|Drug: Comparator : fluticasone propionate / Duration of Treatment: 1 Year|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of asthma with MK0476 and Fluticasone as measured by number of asthma rescue-free days |  | Duration of Trial | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improved effect of MK0476 and fluticasone on FEV1 values |  | Duration of Trial |
Utility of Presepsin in Distinguishing Between Sepsis and SIRS

Study Overview
=================
Brief Summary
-----------------
This is an observational study to evaluate the diagnostic accuracy of presepsin levels to discriminate between sepsis and SIRS upon presentation with critical illness compatible with either sepsis or systemic inflammatory response syndrome (SIRS).

Official Title
-----------------
Utility of Presepsin in Distinguishing Between Sepsis and SIRS (Systemic Inflammatory Response Syndrome): an Exploratory, Prospective Observational Study in Critically Ill Patients

Conditions
-----------------
SIRS, Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Sepsis/SIRS Patients Inclusion Criteria: Male or female aged ≥ 21 years Appropriate clinical data to enable classification into sepsis or SIRS Written informed consent by the patient or legally authorized representative Critical illness consistent with SIRS or sepsis, to be enrolled within 18 hours of presentation Exclusion Criteria: No informed consent Unacceptable risk imposed by extra blood sampling, such as by gross hemorrhage with a hematocrit < 20% Control Inclusion Criteria: Male or female aged ≥ 21 years Does not meet clinical criteria for sepsis or SIRS Written informed consent by the patient or legally authorized representative Exclusion Criteria: No informed consent Unacceptable risk imposed by extra blood sampling, such as by gross hemorrhage with a hematocrit < 20% End Stage Renal Disease Inclusion Criteria: Male or female aged ≥ 21 years Documented diagnosis of end stage renal disease currently undergoing dialysis Does not meet clinical criteria for sepsis or SIRS Written informed consent by the patient or legally authorized representative Exclusion Criteria: No informed consent Unacceptable risk imposed by extra blood sampling, such as by gross hemorrhage with a hematocrit < 20%

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sepsis/SIRS<br>Patients with sepsis or SIRS | |
| Control<br>Patients without SIRS, sepsis, or end stage renal disease | |
| End Stage Renal Disease<br>Patients with end stage renal disease, without SIRS or sepsis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between SIRS and Sepsis | For the analysis, plasma presepsin levels on Day 0 were used and Sepsis/SIRS adjudication was made on Day 7 or day of discharge. ROC-AUC of presepsin for discriminating between SIRS and sepsis is compared to that of procalcitonin. | Up to 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Presepsin, Sepsis, SIRS
Analysis of the Stress Induced by in Situ Simulation

Study Overview
=================
Brief Summary
-----------------
Vulnerability to psychologic distress induced by in situ simulation. Objectives: Psychological evaluation at short and long term on working satisfaction, mental health, and acute stress after in situ simulation. Analysis of the stress vulnerability induced by simulation. Design: non interventional study. Primary outcome: Psychologic distress analysis with validated psychologic distress inventory (Job Satisfaction Survey (JSS), General Health Quality (GHQ), Impact of Event Scale Revisited (IESR), State-Trait Anxiety Inventory-A (STAI-A), State-Trait Anxiety Inventory -B (STAI-B)).

Official Title
-----------------
Analysis of the Stress Induced by in Situ Simulation

Conditions
-----------------
Psychologic Stress, Heart Arrest

Intervention / Treatment
-----------------
* Other: distress analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: team members: nurses, auxiliary nurse, residents, doctors, students Exclusion Criteria: non volunteers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: distress analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| psychologic distress analysis induced by in situ simulation | auto-validated distress inventory: IESR-R STAI-A STAI-B GHQ-12 JSS | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stress vulnerability to in situ simulation | distress inventory: JSS STAI-A social questionary | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
in situ simulation, in hospital cardiac arrest, clinical audit, education, patient simulation